Tetrabenazine
Alternative Names: BVF-018; Choreazine Tablets 12.5mg; Nitoman; Xenazina; Xenazine; Xenazine 25Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator LifeHealth Limited
- Developer AFT Pharmaceuticals; Alfresa Pharma Corporation; ApotheekZorg; Cambridge Laboratories; Chiesi Farmaceutici; EUSA Pharma; Lundbeck A/S; Medilink Pharmaceuticals; Orphan Australia; Temmler Pharma; UCB; Valeant Canada
- Class Antipsychotics; Quinolizines; Small molecules
- Mechanism of Action Dopamine receptor antagonists; Vesicular monoamine transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Huntington's disease; Movement disorders; Tardive dyskinesia
- Discontinued Gilles de la Tourette's syndrome
Most Recent Events
- 12 Jun 2012 EUSA Pharma has been acquired by Jazz Pharmaceuticals plc
- 28 Sep 2010 Biovail Corporation merged with Valeant Pharmaceuticals International forming Valeant Pharmaceuticals International
- 19 May 2009 Biovail Corporation enters into an agreement to acquire tetrabenazine from Cambridge Laboratories